E Seminari

Summary

Affiliation: University of Pavia
Country: Italy

Publications

  1. ncbi Etravirine for the treatment of HIV infection
    E Seminari
    Clinical Epidemiology and Biometric Unit, Fondazione IRCCS Policlinico San Matteo Pavia, P le Golgi 2, I 27100 Pavia, Italy
    Expert Rev Anti Infect Ther 6:427-33. 2008
  2. ncbi Differences in implementation of HIV/AIDS clinical research in developed versus developing world: an evidence-based review on protease inhibitor use among women and minorities
    E Seminari
    Clinic of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Piazzale Golgi 2 27100 Pavia, Italy
    Int J STD AIDS 23:837-42. 2012
  3. ncbi CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis
    Elena Seminari
    Clinical Epidemiology and Biometric Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    AIDS Rev 10:236-44. 2008
  4. ncbi Hepatitis C infection on immune recovery in HIV-positive patients on successful HAART: the role of genotype 3
    Elena Seminari
    Servizio Biometria ed Epidemiologia Clinica Direzione Scientifica Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
    Curr HIV Res 8:186-93. 2010
  5. ncbi Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients
    M B Regazzi
    Department of Pharmacology and Department of Infectious Diseases, IRCCS Policlinico S Matteo, P le Golgi 2, 27100 Pavia, Italy
    J Antimicrob Chemother 45:343-7. 2000
  6. ncbi Role of hydroxyurea during structured treatment interruptions
    A Foli
    Research Institute for Genetic and Human Therapy (RIGHT) at IRCCS Policlinico S Matteo, Pavia, Italy
    J Biol Regul Homeost Agents 16:64-8. 2002
  7. ncbi Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors
    E Seminari
    Department of Infectious Diseases, IRCCS, Policlinico S. Matteo, 27100, Pavia, Italy
    Atherosclerosis 162:433-8. 2002
  8. ncbi Nelfinavir suspension obtained from nelfinavir tablets has equivalent pharmacokinetic profile
    M B Regazzi
    Department of Pharmacology, I R C C S Policlinico San Matteo, University of Pavia, Italy
    J Chemother 13:569-74. 2001
  9. ncbi Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients
    E Seminari
    Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy
    HIV Med 6:145-50. 2005

Collaborators

Detail Information

Publications9

  1. ncbi Etravirine for the treatment of HIV infection
    E Seminari
    Clinical Epidemiology and Biometric Unit, Fondazione IRCCS Policlinico San Matteo Pavia, P le Golgi 2, I 27100 Pavia, Italy
    Expert Rev Anti Infect Ther 6:427-33. 2008
    ..Furthermore, the overall rate of discontinuation due to any adverse event was similar between the etravirine and placebo groups. The most common adverse events reported were rash and nausea...
  2. ncbi Differences in implementation of HIV/AIDS clinical research in developed versus developing world: an evidence-based review on protease inhibitor use among women and minorities
    E Seminari
    Clinic of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Piazzale Golgi 2 27100 Pavia, Italy
    Int J STD AIDS 23:837-42. 2012
    ..7% versus 27.1%, respectively, P = 0.04). Rates of enrolment of minorities in registrative clinical trials for Pls show a positive trend since 1996, mirroring the growing number of people of different ethnic groups accessing ART...
  3. ncbi CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis
    Elena Seminari
    Clinical Epidemiology and Biometric Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    AIDS Rev 10:236-44. 2008
    ....
  4. ncbi Hepatitis C infection on immune recovery in HIV-positive patients on successful HAART: the role of genotype 3
    Elena Seminari
    Servizio Biometria ed Epidemiologia Clinica Direzione Scientifica Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
    Curr HIV Res 8:186-93. 2010
    ..The primary objective of this study was to investigate the impact of HCV infection and of HCV genotypes on immune restoration in HIV-infected patients on a successful HAART regimen...
  5. ncbi Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients
    M B Regazzi
    Department of Pharmacology and Department of Infectious Diseases, IRCCS Policlinico S Matteo, P le Golgi 2, 27100 Pavia, Italy
    J Antimicrob Chemother 45:343-7. 2000
    ....
  6. ncbi Role of hydroxyurea during structured treatment interruptions
    A Foli
    Research Institute for Genetic and Human Therapy (RIGHT) at IRCCS Policlinico S Matteo, Pavia, Italy
    J Biol Regul Homeost Agents 16:64-8. 2002
    ..In this manuscript in vitro and in vivo data indicating that HU might play a major role in the setting of STI-HAART will be presented...
  7. ncbi Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors
    E Seminari
    Department of Infectious Diseases, IRCCS, Policlinico S. Matteo, 27100, Pavia, Italy
    Atherosclerosis 162:433-8. 2002
    ..Moreover, physicians should address concurrent risk factor for atherosclerosis that can be modified, including smoking, hypertension, obesity and sedentary life-style...
  8. ncbi Nelfinavir suspension obtained from nelfinavir tablets has equivalent pharmacokinetic profile
    M B Regazzi
    Department of Pharmacology, I R C C S Policlinico San Matteo, University of Pavia, Italy
    J Chemother 13:569-74. 2001
    ..There was no significant difference in Tmax between the liquid and tablets. Nelfinavir suspension might be a option for treating HIV-infected patients with swallowing disturbances or compliance problems...
  9. ncbi Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients
    E Seminari
    Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy
    HIV Med 6:145-50. 2005
    ..To characterize osteoprotegerin (OPG) levels, bone remodelling and bone mineral density (BMD) in heavily pretreated HIV-infected patients on antiretroviral therapy, and to evaluate the clinical factors associated with bone density decline...